Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation...

2021-04-29 08:34 3241

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

SHANGHAI, China and GAITHERSBURG, U.S., April 13, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-04-13 08:00 3263

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2021-04-12 08:00 2802

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma

SHANGHAI and HONG KONG, April 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-04-06 08:00 8695

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" o...

2021-03-26 08:00 3742

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limi...

2021-03-25 23:26 3517

Antengene Appoints Kevin Lynch as Chief Medical Officer

Antengene Appoints Bo Shan as Chief Scientific Officer

SHANGHAI, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK)...

2021-03-25 22:36 3999

Antengene Appoints Bo Shan as Chief Scientific Officer

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Ante...

2021-03-22 08:00 2903

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Antengene Included in the Shenzhen-Hong Kong Stock Connect

SHANGHAI and HONG KONG, March 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene",...

2021-03-15 09:40 3475

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

SHANGHAI and SEOUL, South Korea, March 15, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Ant...

2021-03-15 08:00 3650

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-03-01 08:00 2696

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-03-01 08:00 5861

Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA

SHANGHAI and HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-02-24 08:00 3071

Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

SHANGHAI and HONG KONG, Feb. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-02-01 08:09 4766

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-01-28 08:00 2738

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-01-28 08:00 4903

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-01-25 08:20 2714

Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

SHANGHAI and SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...

2021-01-11 07:26 1740

Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-01-05 08:00 3230

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-01-04 08:00 4108